The VC who placed a $26.5 million bet on Uber in 2011 is now leading a $7.5 million investment round in Cue, a San Diego startup developing a wireless diagnostic device that enables consumers to run clinical lab tests at home to measure their own health.
In a statement from Cue yesterday, Sherpa Ventures managing director Shervin Pishevar said the five-year-old company is taking a unique approach to consumer health, and “is a prime example of the ‘on demand’ economy applied to health and wellness.”
En el interior de los edificios convivimos con elementos que amenazan la calidad del aire que respiramos. Compuestos como el benceno y el formaldehido, provenientes de productos de limpieza, cosméticos, barnices o pinturas, flotan en el entorno junto con otros contaminantes más propios del exterior (monóxido de carbono, óxidos de nitrógeno).
Frustrated at the lack of interest by the medical establishment in reducing the costs of diagnostic testing, and seeing almost no chance of getting the necessary research grants, Kanav Kahol returned home to New Delhi in 2011. He was a member of Arizona State University’s department of biomedical informatics. Kahol had noted that, despite the similarities between most medical devices in their computer displays and circuits, their packaging made them unduly complex and difficult for anyone but highly skilled practitioners to use. And they were incredibly expensive — costing tens of thousands of dollars each.
A new report on medicines shortages experienced in European healthcare systems published on Monday (17 November) by the European Association of Hospital Pharmacists (EAHP) reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines in the EU.
The EAHP surveyed the experiences of over 600 hospital pharmacists in 36 European countries. Its report presents a gloomy picture of how medicines shortages are affecting the treatment of patients across the continent.
Omega-3 supplements help reduce the number of cigarettes that addicts smoke in a given day, a new Israeli study found.
The study, conducted by Dr. Sharon Rabinovitz Shenkar of the University of Haifa, indicated that the fish oil capsules significantly reduced nicotine craving and helped participants cut down their cigarette consumption by at least 11 percent.
According to Rabinovitz Shenkar, head of the addictions program at the University of Haifa’s School of Criminology, current medications used to help quit smoking are not effective and carry adverse effects.
ONL Therapeutics, a University of Michigan spin-out biopharmaceutical startup working on sight-preserving therapies for retinal diseases, announced today that it has won a $1.3 million Small Business Innovation Research (SBIR) Phase II award from the National Eye Institute.
The SBIR funding will go toward the development of ONL101, a small-molecule peptide initially created for the protection of photoreceptors in retinal detachment—a condition that has earned an orphan disease designation from the FDA—and getting the drug to human clinical trials.
Cellular Dynamics International CEO Bob Palay envisions a world where the eyes of a person going blind from macular degeneration can be healed by implanting healthy retinal cells that were engineered from the patient’s own blood or skin.
That scenario will still require at least several years and untold millions of research dollars, but it’s not as far-fetched as it might at first sound. Indeed, Palay believes science is finally on the verge of unlocking the door to regenerative medicine—and he thinks his company’s manufactured cells hold the key.
Pour les millions de personnes souffrant de sécheresse oculaire, le seul recours pour atténuer la douleur et l'irritation est d'appliquer un collyre 3 fois par jour.
It’s been pretty clear for some time that there’s a big need to improve the efficiency of drug R&D. By industry’s count, drugs cost over $1 billion to develop, and most of them fail. A big reason why is the preclinical studies in petri dishes and animals don’t accurately predict how a drug will behave in humans.
Une équipe de recherche japonaise, dirigée par le professeur Jun Yamashita, a annoncé le 30 octobre 2014 qu'elle allait développer une nouvelle technologie permettant de produire et de vendre des cellules musculaires cardiaques obtenues à partir de cellules pluripotentes induites (iPS) humaines, dans le but de tester de nouveaux médicaments. Ce projet a été lancé par l'Organisation pour le développement des nouvelles énergies et des technologies industrielles (NEDO) ainsi que par le Centre de recherche sur les cellules iPS de Kyoto (CiRA) et trois entreprises privées, dont Takara Bio Inc.
